angiotensin ii and sildenafil citrate

Topics: Angiotensin II; Carbolines; Cardiovascular Diseases; Delayed-Action Preparations; Erectile Dysfunction; Humans; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil

Topics: Angiotensin II; Animals; Caffeine; Calcium; Calcium Signaling; Chronic Disease; Disease Models, Animal; Hypertension, Pulmonary; Hypoxia; Male; Muscle, Smooth, Vascular; Phenylephrine; Phosphodiesterase Inhibitors; Piperazines; Pulmonary Artery; Purines; Rats; Rats, Wistar; Sildenafil Citrate; Sulfones; Vasoconstriction; Vasoconstrictor Agents

Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Anastomosis, Surgical; Angiopoietin-1; Angiotensin II; Animals; Arterioles; Bone Morphogenetic Protein Receptors, Type I; Bone Morphogenetic Protein Receptors, Type II; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Evaluation, Preclinical; Endothelin-1; Gene Expression Regulation; Hyperplasia; Hypertension, Pulmonary; Models, Animal; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Protein Serine-Threonine Kinases; Pulmonary Artery; Purines; Random Allocation; Receptors, Growth Factor; RNA, Messenger; Signal Transduction; Sildenafil Citrate; Subclavian Artery; Sulfones; Sus scrofa; Vascular Endothelial Growth Factor A

Topics: Analysis of Variance; Angiotensin II; Animals; Antihypertensive Agents; Arteries; Blood Pressure; Blotting, Western; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 1; Dose-Response Relationship, Drug; Hypertension; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Vasoconstriction; Vinca Alkaloids

Topics: Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Cyclic GMP-Dependent Protein Kinase Type I; Cyclic Nucleotide Phosphodiesterases, Type 5; Cytokines; Extracellular Matrix; Heart Failure; Heart Function Tests; Hydralazine; Male; Mice; Mice, Inbred C57BL; Myocarditis; Myocardium; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Sildenafil Citrate; Sulfones; Vasoconstrictor Agents; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling

Topics: Angiotensin II; Animals; Blood Pressure; Body Weight; Comet Assay; Constriction, Pathologic; DNA Damage; Heart Rate; Hypertension, Renovascular; Kidney; Kidney Function Tests; Mice; Mice, Inbred C57BL; Organ Size; Oxidative Stress; Piperazines; Purines; Reactive Oxygen Species; Renal Artery; Sildenafil Citrate; Sulfones

Topics: Actins; Angiotensin II; Animals; Cadherins; Cells, Cultured; Culture Media, Conditioned; Cyclic GMP-Dependent Protein Kinase Type I; Cytokines; Disease Models, Animal; Fibrosis; Inflammation Mediators; Kidney Diseases; Kidney Tubules, Proximal; Macrophages; Male; Mice; Mice, Transgenic; Phosphodiesterase 5 Inhibitors; Phosphorylation; Piperazines; Purines; Signal Transduction; Sildenafil Citrate; Smad2 Protein; Sulfones; Time Factors; Transforming Growth Factor beta1; Up-Regulation; Ureteral Obstruction

Topics: Angiotensin II; Animals; Cardiomegaly; Cyclic GMP; Cyclic GMP-Dependent Protein Kinase Type I; Cyclic Nucleotide Phosphodiesterases, Type 5; Fibrosis; Genetic Markers; Hypertension; Mice; Muscle, Smooth; Myocardial Contraction; Myocytes, Cardiac; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Vasoconstrictor Agents

Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Animals; Cardiomegaly; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Fibrosis; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myocytes, Cardiac; Piperazines; Purines; Receptor, Angiotensin, Type 1; Signal Transduction; Sildenafil Citrate; Sulfonamides; Up-Regulation

Topics: Angiotensin II; Animals; Apoptosis; Cardiopulmonary Resuscitation; Cardiotonic Agents; Cyclic GMP; Disease Models, Animal; Gene Expression Regulation; Heart Arrest; Hemodynamics; Male; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Peptidyl-Dipeptidase A; Phosphodiesterase 5 Inhibitors; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Sildenafil Citrate; Swine

Topics: Angiotensin II; Angiotensins; Animals; Blood Pressure; Disease Models, Animal; Female; Humans; Male; Mice; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type III; Oxidative Stress; Phosphorylation; Placenta; Pre-Eclampsia; Pregnancy; Pregnancy, Animal; Signal Transduction; Sildenafil Citrate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1

Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cyclic GMP; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension; Male; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphodiesterase 5 Inhibitors; Renal Artery; Renal Circulation; Sildenafil Citrate; Vasodilation; Vasodilator Agents; Vinca Alkaloids

Topics: Angiotensin II; Animals; Hypertension; Male; Mesenteric Arteries; Mice; Mice, Inbred C57BL; Phosphodiesterase 5 Inhibitors; Reactive Oxygen Species; Sildenafil Citrate

Topics: Angiogenesis Inhibitors; Angiotensin II; Animals; Diosmin; Drug Synergism; Fibroblast Growth Factor 1; Hepatopulmonary Syndrome; Insulin-Like Growth Factor I; Male; Pentoxifylline; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Signal Transduction; Sildenafil Citrate; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A